Patent · US Active

Glycosylated VWF fusion proteins with improved pharmacokinetics

US12171808B2 · kind B2 · utility

0Cited by

0References

28Claims

0Family size

Assignee

OCTAPHARMA AG · CH

Inventors

Christoph Kannicht · Berlin, DE
Barbara Solecka-Witulska · Berlin, DE
Stefan Winge · Kramfors, SE
Tilo Schwientek · Copenhagen, DK

Key dates

Filing date	Apr 26, 2017
Grant date	Dec 24, 2024
Priority date	—
Expiry date	Mar 20, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/35
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.